The Intersection of Health Economics, AI and Health Outcomes
By Sumona Bose
February 1, 2024
Introduction
In recent years, the healthcare industry has witnessed a surge in the use of artificial intelligence (AI) technologies to improve patient care and outcomes. As the field of health economics and outcomes research (HEOR) continues to evolve, it is crucial to understand the economic evaluations of AI-based health interventions. A recent study conducted by Voets et al. provides valuable insights into the current landscape of AI in healthcare. This article aims to summarize the key findings of the study and shed light on the merged perspectives of HEOR, AI, and health outcomes. The application of Health Economics in AI allows us to analyse a balanced view of how intrinsic digital innovation is in the healthcare landscape. This article authored by Vithlani et al., builds on the progressive work of Voets et al.
Relevance of Economic Evaluations
Economic evaluations play a crucial role in assessing the value of AI-based health interventions. The original review by Voets et al. found that cost minimization was the prevailing type of health economic evaluation (HEE). However, the updated review reveals a shift towards cost-utility analysis (CUA) as the most common study type. This change suggests a growing emphasis on assessing the broader economic and health outcomes of AI interventions. The application of Health Economics into AI brings about numerous debates on how evaluative methodologies are efficient.
Model-Based Evaluations
The updated review also highlights a significant difference in the use of model-based evaluations compared to the original review. The study found that 45% of the HEEs were model-based, the updated review indicates that the large majority of HEEs now employ this approach. Model-based evaluations allow for estimating future costs and benefits of AI technologies.
Figure 1: Summary of economic evaluation parameters and outcomes.
Limitations and Reporting Standards
Despite the increase in the use of sophisticated economic evaluation techniques, the evidence supporting these methods remains limited. The quality assessment conducted in the study revealed potentially serious limitations in the sources and assumptions regarding input data. The reporting of HEEs also lacked clarity, making it challenging to determine fundamental aspects such as cost application, integration with clinical care, and anticipated users of AI interventions.
Conclusion
The intersection of health economics, AI, and health outcomes is a rapidly evolving field with significant implications for the healthcare industry. The study conducted by Voets et al. provides valuable insights into the current landscape of AI in healthcare. It highlights the need for economic evaluations of AI-based health interventions. It found that AI health technologies are on the rise, with automated image analysis being the most commonly evaluated purpose of AI interventions. The shift towards cost-utility analysis suggests a growing emphasis on assessing the broader economic and health outcomes of AI interventions.
A newly developed implantable glucose device from MIT could revolutionize diabetes management, providing an autonomous solution to prevent life-threatening hypoglycemic episodes. This innovative device combines continuous glucose monitoring with responsive hormone delivery, potentially transforming patient care by reducing the need for constant oversight.
Curious about how this technology could reshape diabetes outcomes and healthcare economics? Dive into the full article for a closer look!
🔍 Have you considered how federated learning governance can revolutionize healthcare data collaboration?
In our latest article, we explore the critical principles of federated learning governance, emphasizing its role in managing decentralized health data while protecting patient privacy and improving research quality. Learn about the actionable strategies healthcare organizations can implement to navigate the unique challenges that come with this innovative approach.
Dive deeper into the world of federated learning in healthcare and unlock its potential for ethical and effective data use!
🌍 Did you know that China has just achieved a historic milestone in the fight against cervical cancer?
The approval of the Cecolin 9 HPV vaccine, the first domestically developed 9-valent HPV vaccine, marks a transformative moment for public health, enhancing access and affordability across the nation. This development not only meets global health goals but also reshapes the landscape of cervical cancer prevention in China.
Curious to learn how this advancement is set to impact vaccination efforts and healthcare economics? Dive into the full article for deeper insights!
#SyenzaNews #globalhealth #HealthEconomics
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management.
You’ll also feel our high-impact global and local perspectives with cultural intelligence.